153 related articles for article (PubMed ID: 22562361)
1. Transepithelial transport of rosuvastatin and effect of ursolic acid on its transport in Caco-2 monolayers.
Hua WJ; Fang HJ; Hua WX
Eur J Drug Metab Pharmacokinet; 2012 Sep; 37(3):225-31. PubMed ID: 22562361
[TBL] [Abstract][Full Text] [Related]
2. Effect of Ursolic Acid on Breast Cancer Resistance Protein-mediated Transport of Rosuvastatin In Vivo and Vitro.
Wen JH; Wei XH; Sheng XY; Zhou DQ; Peng HW; Lu YN; Zhou J
Chin Med Sci J; 2015 Dec; 30(4):218-25. PubMed ID: 26960302
[TBL] [Abstract][Full Text] [Related]
3. The role of a basolateral transporter in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell monolayer systems.
Li J; Wang Y; Zhang W; Huang Y; Hein K; Hidalgo IJ
Drug Metab Dispos; 2012 Nov; 40(11):2102-8. PubMed ID: 22855735
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
5. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin.
Deng JW; Shon JH; Shin HJ; Park SJ; Yeo CW; Zhou HH; Song IS; Shin JG
Pharm Res; 2008 Aug; 25(8):1807-14. PubMed ID: 18236139
[TBL] [Abstract][Full Text] [Related]
6. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
Kitamura S; Maeda K; Wang Y; Sugiyama Y
Drug Metab Dispos; 2008 Oct; 36(10):2014-23. PubMed ID: 18617601
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
9. The effect of herbal medicine danshensu and ursolic acid on pharmacokinetics of rosuvastatin in rats.
Wen JH; Xiong YQ
Eur J Drug Metab Pharmacokinet; 2011 Dec; 36(4):205-11. PubMed ID: 21717139
[TBL] [Abstract][Full Text] [Related]
10. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
[TBL] [Abstract][Full Text] [Related]
11. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
12. Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model.
Hobbs M; Parker C; Birch H; Kenworthy K
Xenobiotica; 2012 Apr; 42(4):327-38. PubMed ID: 22035568
[TBL] [Abstract][Full Text] [Related]
13. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
14. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.
Hu M; To KK; Mak VW; Tomlinson B
Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):49-62. PubMed ID: 21091277
[TBL] [Abstract][Full Text] [Related]
15. Ethnic differences in statin disposition.
Tirona RG
Clin Pharmacol Ther; 2005 Oct; 78(4):311-6. PubMed ID: 16198649
[No Abstract] [Full Text] [Related]
16. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.
Tomita Y; Maeda K; Sugiyama Y
Clin Pharmacol Ther; 2013 Jul; 94(1):37-51. PubMed ID: 23443754
[TBL] [Abstract][Full Text] [Related]
17. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Keskitalo JE; Kurkinen KJ; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2009 Aug; 68(2):207-13. PubMed ID: 19694740
[TBL] [Abstract][Full Text] [Related]
18. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure.
Iusuf D; van Esch A; Hobbs M; Taylor M; Kenworthy KE; van de Steeg E; Wagenaar E; Schinkel AH
Mol Pharmacol; 2013 May; 83(5):919-29. PubMed ID: 23429889
[TBL] [Abstract][Full Text] [Related]
19. Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
Wan Z; Wang G; Li T; Xu B; Pei Q; Peng Y; Sun H; Cheng L; Zeng Y; Yang G; Zhu YS
J Pharmacol Exp Ther; 2015 Sep; 354(3):310-5. PubMed ID: 26081159
[TBL] [Abstract][Full Text] [Related]
20. The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin.
Windass AS; Lowes S; Wang Y; Brown CD
J Pharmacol Exp Ther; 2007 Sep; 322(3):1221-7. PubMed ID: 17585018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
